Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis

Pharmaceutical Research

Volumn 30, Issue 5, 2013, Pages 1349-1361

  Schully, Kevin L ^a   Sharma, Sadhana ^b   Peine, Kevin J ^b   Pesce, John ^a   Elberson, Margret A ^a   Fonseca, Mariko E ^a   Prouty, Angela M ^a   Bell, Matthew G ^a   Borteh, Hassan ^b   Gallovic, Matthew ^c   Bachelder, Eric M ^b   Keane Myers, Andrea ^a   Ainslie, Kristy M ^b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c The Ohio State University   (United States)

Author keywords

anthrax; bacterial vaccine; inhalation anthrax; polymeric nanoparticle microparticle; vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; DEXTRAN DERIVATIVE; DRUG CARRIER; NEUTRALIZING ANTIBODY; RECOMBINANT PROTECTIVE ANTIGEN; RESIQUIMOD; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DEATH; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; HEART; IMMUNE RESPONSE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

ACETYLATION; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DEXTRANS; DRUG CARRIERS; IMIDAZOLES; MICE; TOLL-LIKE RECEPTORS; VACCINATION; VACCINES, SUBUNIT;

EID: 84876493605     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0975-x     Document Type: Article

References (51)

1. Callahan M. DARPA-BAA-09-43: Broad Agency Announcement 7-Day Biodefense In: Agency DARP, editor. Arlington, VA Department of Defense; 2009.
2. Control CfD. Emergency Preparedness and Response: Anthrax. Atlanta: CDC; 2012 [cited 2012 3/8/12]; Available from: http://www.bt.cdc.gov/agent/anthrax/.
3. Bhargava D, Bhargava K, Sabri I, Siddharth M, Dave A, HG J, et al. Bioterrorism - "My Role as a Dentist". J Indian Acad Forensic Med. 2011;33(3):254.
4. Sternbach G. The history of anthrax. J Emerg Med. 2003;24(4):463-7.
5. Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. Ann Allergy Asthma Immunol. 2006;97(1):110-2.
6. Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology. 2004;51(57):762-7.
7. Mercola J. Is An Anthrax Vaccine Worth It? Redwood City: Care2.com, Inc.; 2012 [cited 2012 3/22/12]; Available from: http://www.care2.com/greenliving/is- an-anthrax-vaccine-worth-it.html.
8. Zhang Y, Qiu J, Zhou Y, Farhangfar F, Hester J, Lin AY, et al. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Vaccine. 2008;26(5):614-22.
9. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, et al. Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine. 2011;29(37):6313-20.
10. Klinman DM, Xie H, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci. 2006;1082:137-50.
11. Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine. 2011;29(17):3284-92.
12. Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espindola NM, et al. New malaria vaccine candidates based on the plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist salmonella typhimurium FliC flagellin. Vaccine. 2008;26(48):6132-42.
13. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res. 2006;68:193-253.
14. Almeida AP, Bruna-Romero O. Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria. Mem Inst Oswaldo Cruz. 2011;106 Suppl 1:193-201.
15. Bachelder EM, Beaudette TT, Broaders KE, Frechet JM, Albrecht MT, Mateczun AJ, et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7(3):826-35.
16. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 2000;203(1):55-65.
17. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48(6):751-5.
18. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404-13.
19. Kauffman KJ, Kanthamneni N, Meenach SA, Pierson BC, Bachelder EM, Ainslie KM. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm. 2012;422(1-2):356-63.
20. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol Pharm. 2012;9(2):290-8.
21. Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Frechet JM. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci U S A. 2009;106(14):5497-502.
22. Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science. 1972;178(4063):871-2.
23. Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun. 2007;75(11):5425-33.
24. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of bacillus anthracis toxin. Infect Immun. 1988;56(7):1807-13.
25. Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, et al. Immune responses to bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis. 2004;190(7):1228-36.
26. Li H, Soroka SD, Taylor Jr TH, Stamey KL, Stinson KW, Freeman AE, et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods. 2008;333(1-2):89-106.
27. Stojkovic B, Torres EM, Prouty AM, Patel HK, Zhuang L, Koehler TM, et al. High-throughput, single-cell analysis of macrophage interactions with fluorescently labeled bacillus anthracis spores. Appl Environ Microbiol. 2008;74(16):5201-10.
28. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315-22.
29. Hirota K, Hasegawa T, Hinata H, Ito F, Inagawa H, Kochi C, et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release. 2007;119(1):69-76.
30. Bachelder EM, Beaudette TT, Broaders KE, Dashe J, Frechet JM. Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J Am Chem Soc. 2008;130(32):10494-5.
31. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4-5):394-407.
32. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A. 1993;90(11):4942-6.
33. Kanthamneni N, Sharma S, Meenach SA, Billet B, Zhao JC, Bachelder EM, et al. Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain conditions. Int J Pharm. 2012;431(1-2):101-10.
34. Lu L, Peter SJ, Lyman MD, Lai HL, Leite SM, Tamada JA, et al. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials. 2000;21(18):1837-45.
35. Liu Y. Schwendeman SP. Mol Pharm: Mapping microclimate pH distribution inside protein-encapsulated PLGA microspheres using confocal laser scanning microscopy; 2012.
36. Szoka Jr FC. The future of liposomal drug delivery. Biotechnol Appl Biochem. 1990;12(5):496-500.
37. Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin. 2010;6(7):585-94.
38. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44(1):68-97.
39. Janeway C, Travers P, Walport M, Shlomchik M. ImmunoBiology. 5th ed. New York: Garland Science; 2001.
40. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24(11):1958-65.
41. Paul WE. Fundamental immunology. 4th ed. New York: Raven; 1994.
42. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm. 2007;331(2):228-32.
43. Nemazee DA. Immune complexes can trigger specific, T cell-dependent, autoanti-IgG antibody production in mice. J Exp Med. 1985;161(1):242-56.
44. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther. 2007;15(1):203-10.
45. Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG, Mott JM, et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun. 2005;73(9):5978-87.
46. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616-29.
47. Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett. 2000;74(1):11-25.
48. Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, et al. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther. 2008;15(16):1156-66.
49. Popov SG, Popova TG, Grene E, Klotz F, Cardwell J, Bradburne C, et al. Systemic cytokine response in murine anthrax. Cell Microbiol. 2004;6(3):225-33.
50. Cohen JA, Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, et al. T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Bioconjug Chem. 2009;20(1):111-9.
51. Kwon YJ, James E, Shastri N, Frechet JM. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci U S A. 2005;102(51):18264-8.